Ectopic expression of the TERE1 (UBIAD1) protein inhibits growth of renal clear cell carcinoma cells: Altered metabolic phenotype associated with reactive oxygen species, nitric oxide and SXR target genes involved in cholesterol and lipid metabolism

International Journal of Oncology

Volumn 43, Issue 2, 2013, Pages 638-652

  Fredericks, William J ^a   Yin, Hankun ^a,b   Lal, Priti ^c   Puthiyaveettil, Raghunath ^c   Malkowicz, Stephen B ^a   Fredericks, Nathaniel J ^a   Tomaszewski, John ^d   Rauscher III, Frank J ^e   Malkowicz, S Bruce ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b FUDAN UNIVERSITY   (China)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e WISTAR INSTITUTE   (United States)

Author keywords

Lipid metabolism; Mitochondria; Renal clear cell carcinoma; SXR target genes; TBL2; TERE1; UBIAD1; Vitamin K 2

Indexed keywords

CASPASE 3; CASPASE 7; CHOLESTEROL; LIPID; NITRIC OXIDE; PROTEIN; REACTIVE OXYGEN METABOLITE; TERE 1 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLEAR CELL CARCINOMA; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIPID METABOLISM; MITOCHONDRIAL RESPIRATION; OXIDATION REDUCTION STATE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; CARCINOMA, RENAL CELL; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLESTEROL; DIMETHYLALLYLTRANSTRANSFERASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; HYDROGEN; KIDNEY NEOPLASMS; LIPID METABOLISM; MITOCHONDRIA; NITRIC OXIDE; OXIDATIVE STRESS; OXYGEN; REACTIVE OXYGEN SPECIES; RECEPTORS, STEROID; UBIQUINONE; VITAMIN K 2;

EID: 84879610183     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1985     Document Type: Article

References (110)

1. Li L and Kaelin WG Jr: New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 25: 667-686, 2011.
2. Messer J, Drabick J and Kaag M: Rational therapy for renal cell carcinoma based on its genetic targets. Adv Exp Med Biol 779: 291-308, 2013.
3. Pischon T, Nöthlings U and Boeing H: Obesity and cancer. Proc Nutr Soc 67: 128-145, 2008.
4. Drabkin HA and Gemmill RM: Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC). Adv Cancer Res 107: 39-56, 2010.
5. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M and De Bruine AP: VHL and HIF signalling in renal cell carcinogenesis. J Pathol 221: 125-138, 2010.
6. Keith B, Johnson RS and Simon MC: HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22, 2012.
7. Banumathy G and Cairns P: Signaling pathways in renal cell carcinoma. Cancer Biol Ther 10: 658-664, 2010.
8. Linehan WM, Bratslavsky G, Pinto PA, et al: Molecular diagnosis and therapy of kidney cancer. Annu Rev Med 61: 329-343, 2010.
9. Mihaly Z, Sztupinszki Z, Surowiak P and Gyorffy B: A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. Curr Cancer Drug Targets 12: 857-872, 2012.
10. Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ and Quinn DI: Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther 11: 526-537, 2012.
11. Gebhard RL, Clayman RV, Prigge WF, et al: Abnormal cholesterol metabolism in renal clear cell carcinoma. J Lipid Res 28: 1177-1184, 1987. (Pubitemid 17151580)
12. Christenson E, Merlin S, Saito M and Schlesinger P: Cholesterol effects on BAX pore activation. J Mol Biol 381: 1168-1183, 2008.
13. Li YC, Park MJ, Ye SK, Kim CW and Kim YN: Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 168: 1107-1118, 2006.
14. Martinez-Abundis E, Garcia N, Correa F, Franco M and Zazueta C: Changes in specific lipids regulate BAX-induced mitochondrial permeability transition. FEBS J 274: 6500-6510, 2007. (Pubitemid 350215937)
15. Oh HY, Lee EJ, Yoon S, Chung BH, Cho KS and Hong SJ: Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. Prostate 67: 1061-1069, 2007. (Pubitemid 46991915)
16. Swinnen JV, Brusselmans K and Verhoeven G: Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9: 358-365, 2006. (Pubitemid 44101970)
17. Prenen H, Gil T and Awada A: New therapeutic developments in renal cell cancer. Crit Rev Oncol Hematol 69: 56-63, 2009.
18. Srinivasan R, Armstrong AJ, Dahut W and George DJ: Anti-angiogenic therapy in renal cell cancer. BJU Int 99: 1296-1300, 2007. (Pubitemid 46624178)
19. Selak MA, Armour SM, MacKenzie ED, et al: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7: 77-85, 2005. (Pubitemid 40126384)
20. Ashrafian H, O'Flaherty L, Adam J, et al: Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis. Cancer Res 70: 9153-9165, 2010.
21. O'Flaherty L, Adam J, Heather LC, et al: Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. Hum Mol Genet 19: 3844-3851, 2010.
22. Yang Y, Valera VA, Padilla-Nash HM, et al: UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet 196: 45-55, 2010.
23. Nakagawa K, Hirota Y, Sawada N, et al: Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature 468: 117-121, 2010.
24. Fredericks WJ, McGarvey T, Wang H, et al: The TERE1 (UBIAD1) bladder tumor suppressor protein interacts with mitochondrial TBL2: regulation of trans-membrane potential, oxidative stress and SXR signaling to the nucleus. J Cell Biochem doi: 10.1002/jcb.24567, 2013 [Epub ahead of print].
25. McGarvey TW, Nguyen T, Tomaszewski JE, Monson FC and Malkowicz SB: Isolation and characterization of the TERE1 gene, a gene down-regulated in transitional cell carcinoma of the bladder. Oncogene 20: 1042-1051, 2001. (Pubitemid 32238853)
26. McGarvey TW, Nguyen T, Puthiyaveettil R, Tomaszewski JE and Malkowicz SB: TERE1, a novel gene affecting growth regulation in prostate carcinoma. Prostate 54: 144-155, 2003. (Pubitemid 36120330)
27. Fredericks WJ, McGarvey T, Wang H, et al: The bladder tumor suppressor protein TERE1 (UBIAD1) modulates cell cholesterol: implications for tumor progression. DNA Cell Biol 30: 851-864, 2011.
28. McGarvey TW, Nguyen TB and Malkowicz SB: An interaction between apolipoprotein E and TERE1 with a possible association with bladder tumor formation. J Cell Biochem 95: 419-428, 2005. (Pubitemid 41420209)
29. Weiss JS, Kruth HS, Kuivaniemi H, et al: Mutations in the UBIAD1 gene on chromosome short arm 1, region 36, cause Schnyder crystalline corneal dystrophy. Invest Ophthalmol Vis Sci 48: 5007-5012, 2007. (Pubitemid 351260910)
30. Nickerson ML, Kostiha BN, Brandt W, et al: UBIAD1 mutation alters a mitochondrial prenyltransferase to cause Schnyder corneal dystrophy. PLoS One 5: e10760, 2010.
31. Nickerson ML, Bosley AD, Weiss JS, et al: The UBIAD1 prenyltransferase links menaquione-4 synthesis to cholesterol metabolic enzymes. Hum Mutat 34: 317-329, 2013.
32. Ihunnah CA, Jiang M and Xie W: Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim Biophys Acta 1812: 956-963, 2011.
33. Zhou C, Verma S and Blumberg B: The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal 7: e001, 2009.
34. Lamson DW and Plaza SM: The anticancer effects of vitamin K. Altern Med Rev 8: 303-318, 2003. (Pubitemid 37099889)
35. Nishikawa Y, Wang Z, Kerns J, Wilcox CS and Carr BI: Inhibition of hepatoma cell growth in vitro by arylating and non-arylating K vitamin analogs. Significance of protein tyrosine phosphatase inhibition. J Biol Chem 274: 34803-34810, 1999. (Pubitemid 129509524)
36. Gilloteaux J, Jamison JM, Neal DR, Loukas M, Doberzstyn T and Summers JL: Cell damage and death by autoschizis in human bladder (RT4) carcinoma cells resulting from treatment with ascorbate and menadione. Ultrastruct Pathol 34: 140-160, 2010.
37. Nowicka B and Kruk J: Occurrence, biosynthesis and function of isoprenoid quinones. Biochim Biophys Acta 1797: 1587-1605, 2010.
38. Tielens AG, Rotte C, van Hellemond JJ and Martin W: Mitochondria as we don't know them. Trends Biochem Sci 27: 564-572, 2002. (Pubitemid 35335405)
39. Vos M, Esposito G, Edirisinghe JN, et al: Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. Science 336: 1306-1310, 2012.
40. Spurgeon SL, Jones RC and Ramakrishnan R: High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One 3: e1662, 2008.
41. Mugoni V, Postel R, Catanzaro V, et al: Ubiad1 is an antioxidant enzyme that regulates eNOS activity by CoQ10 synthesis. Cell 152: 504-518, 2013.
42. Jamin N, Neumann JM, Ostuni MA, et al: Characterization of the cholesterol recognition amino acid consensus sequence of the peripheral-type benzodiazepine receptor. Mol Endocrinol 19: 588-594, 2005. (Pubitemid 40349433)
43. Hulce JJ, Cognetta AB, Niphakis MJ, Tully SE and Cravatt BF: Proteome-wide mapping of cholesterol-interacting proteins in mammalian cells. Nat Methods 10: 259-264, 2013.
44. Wu M, Neilson A, Swift AL, et al: Multiparameter metabolic analysis reveals a close l link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 292: C125-C136, 2007. (Pubitemid 46115126)
45. Klaus V, Hartmann T, Gambini J, et al: 1,4-Naphthoquinones as inducers of oxidative damage and stress signaling in HaCaT human keratinocytes. Arch Biochem Biophys 496: 93-100, 2010.
46. Sano M, Fujita H, Morita I, Uematsu H and Murota S: Vitamin K2 (menatetrenone) induces iNOS in bovine vascular smooth muscle cells: no relationship between nitric oxide production and gamma-carboxylation. J Nutr Sci Vitaminol (Tokyo) 45: 711-723, 1999. (Pubitemid 30141297)
47. Bhalerao S and Clandinin TR: Cell biology. Vitamin K2 takes charge. Science 336: 1241-1242, 2012.
48. Shearer MJ and Newman P: Metabolism and cell biology of vitamin K. Thromb Haemost 100: 530-547, 2008.
49. Zhou C, King N, Chen KY and Breslow JL: Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. J Lipid Res 50: 2004-2013, 2009.
50. Landes N: Homologous metabolic and gene activating routes for vitamins E and K. Mol Aspects Med 24: 337-344, 2003.
51. Lim YP and Huang JD: Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet 23: 14-21, 2008.
52. Brown AJ and Jessup W: Oxysterols: sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Mol Aspects Med 30: 111-122, 2009.
53. Sonoda J, Chong LW, Downes M, et al: Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proc Natl Acad Sci USA 102: 2198-2203, 2005. (Pubitemid 40262035)
54. Wang Y, Rogers PM, Su C, Varga G, Stayrook KR and Burris TP: Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha. J Biol Chem 283: 26332-26339, 2008.
55. Wang X and Rader DJ: Molecular regulation of macrophage reverse cholesterol transport. Curr Opin Cardiol 22: 368-372, 2007. (Pubitemid 46897290)
56. Wang X, Collins HL, Ranalletta M, et al: Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 117: 2216-2224, 2007. (Pubitemid 47219566)
57. Lordan S, Mackrill JJ and O'Brien NM: Oxysterols and mechanisms of apoptotic signaling: implications in the pathology of degenerative diseases. J Nutr Biochem 20: 321-336, 2009.
58. Shibayama-Imazu T, Aiuchi T and Nakaya K: Vitamin K2-mediated apoptosis in cancer cells: role of mitochondrial transmembrane potential. Vitam Horm 78: 211-226, 2008.
59. Jamison JM, Gilloteaux J, Nassiri MR, Venugopal M, Neal DR and Summers JL: Cell cycle arrest and autoschizis in a human bladder carcinoma cell line following Vitamin C and Vitamin K3 treatment. Biochem Pharmacol 67: 337-351, 2004. (Pubitemid 38112764)
60. Jamison JM, Gilloteaux J, Perlaky L, et al: Nucleolar changes and fibrillarin redistribution following apatone treatment of human bladder carcinoma cells. J Histochem Cytochem 58: 635-651, 2010.
61. Karasawa S, Azuma M, Kasama T, et al: Vitamin K2 covalently binds to Bak and induces Bak-mediated apoptosis. Mol Pharmacol 83: 613-620, 2013.
62. Dranka BP, Hill BG and Darley-Usmar VM: Mitochondrial reserve capacity in endothelial cells: the impact of nitric oxide and reactive oxygen species. Free Radic Biol Med 48: 905-914, 2010.
63. Benz CC, Atsriku C, Yau C, et al: Novel pathways associated with quinone-induced stress in breast cancer cells. Drug Metab Rev 38: 601-613, 2006. (Pubitemid 44903257)
64. Bolton JL, Trush MA, Penning TM, Dryhurst G and Monks TJ: Role of quinones in toxicology. Chem Res Toxicol 13: 135-160, 2000. (Pubitemid 30169958)
65. Lamson DW, Gu YH, Plaza SM, Brignall MS, Brinton CA and Sadlon AE: The vitamin C: vitamin K3 system - enhancers and inhibitors of the anticancer effect. Altern Med Rev 15: 345-351, 2010.
66. Ambs S and Glynn SA: Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer. Cell Cycle 10: 619-624, 2011.
67. Lee J, Giordano S and Zhang J: Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J 441: 523-540, 2012.
68. Doulias PT, Tenopoulou M, Greene JL, Raju K and Ischiropoulos H: Nitric oxide regulates mitochondrial fatty acid metabolism through reversible protein S-nitrosylation. Sci Signal 6: rs1, 2013.
69. Lusini L, Tripodi SA, Rossi R, et al: Altered glutathione anti-oxidant metabolism during tumor progression in human renal-cell carcinoma. Int J Cancer 91: 55-59, 2001.
70. Fitzgerald JP, Nayak B, Shanmugasundaram K, et al: Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production. PLoS One 7: e30712, 2012.
71. Abdelmohsen K: Epidermal growth factor receptor is a common mediator of quinone-induced signaling leading to phosphorylation of connexin-43: Role of glutathione and tyrosine phosphatases. J Biol Chem 278: 38360-38367, 2003.
72. Suhara Y, Hanada N, Okitsu T, et al: Structure-activity relationship of novel menaquinone-4 analogues: modification of the side chain affects their biological activities. J Med Chem 55: 1553-1558, 2012.
73. Suhara Y, Watanabe M, Motoyoshi S, et al: Synthesis of new vitamin K analogues as steroid and xenobiotic receptor (SXR) agonists: insights into the biological role of the side chain part of vitamin K. J Med Chem 54: 4918-4922, 2011.
74. Mazurek S: Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 43: 969-980, 2011.
75. Wong N, De Melo J and Tang D: PKM2, a central point of regulation in cancer metabolism. Int J Cell Biol 2013: 242513, 2013.
76. Chen J, Jiang Z, Wang B, Wang Y and Hu X: Vitamin K(3) and K(5) are inhibitors of tumor pyruvate kinase M2. Cancer Lett 316: 204-210, 2012.
77. Anastasiou D, Poulogiannis G, Asara JM, et al: Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334: 1278-1283, 2011.
78. Zaunmuller T, Kelly DJ, Glockner FO and Unden G: Succinate dehydrogenase functioning by a reverse redox loop mechanism and fumarate reductase in sulphate-reducing bacteria. Microbiology 152: 2443-2453, 2006. (Pubitemid 44219650)
79. Sakai C, Tomitsuka E, Esumi H, Harada S and Kita K: Mitochondrial fumarate reductase as a target of chemotherapy: from parasites to cancer cells. Biochim Biophys Acta 1820: 643-651, 2012.
80. Tomitsuka E, Kita K and Esumi H: The NADH-fumarate reductase system, a novel mitochondrial energy metabolism, is a new target for anticancer therapy in tumor microenvironments. Ann NY Acad Sci 1201: 44-49, 2010.
81. Tomitsuka E, Kita K and Esumi H: An anticancer agent, pyrvinium pamoate inhibits the NADH-fumarate reductase system - a unique mitochondrial energy metabolism in tumour microenvironments. J Biochem 152: 171-183, 2012.
82. Tomlinson IP, Alam NA, Rowan AJ, et al: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30: 406-410, 2002.
83. Yang Y, Valera V, Sourbier C, et al: A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genet 205: 377-390, 2012.
84. Ternette N, Yang M, Laroyia M, et al: Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep 3: 689-700, 2013.
85. Barrios-Rodiles M, Brown KR, Ozdamar B, et al: High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307: 1621-1625, 2005. (Pubitemid 40354744)
86. Behrends C, Sowa ME, Gygi SP and Harper JW: Network organization of the human autophagy system. Nature 466: 68-76, 2010.
87. Perez Jurado LA, Wang YK, Francke U and Cruces J: TBL2, a novel transducin family member in the WBS deletion: characterization of the complete sequence, genomic structure, transcriptional variants and the mouse ortholog. Cytogenet Cell Genet 86: 277-284, 1999.
88. Tieu Q and Nunnari J: Mdv1p is a WD repeat protein that interacts with the dynamin-related GTPase, Dnm1p, to trigger mitochondrial division. J Cell Biol 151: 353-366, 2000.
89. Tieu Q, Okreglak V, Naylor K and Nunnari J: The WD repeat protein, Mdv1p, functions as a molecular adaptor by interacting with Dnm1p and Fis1p during mitochondrial fission. J Cell Biol 158: 445-452, 2002. (Pubitemid 34851703)
90. Feng Y, Zhang C, Luo Q, et al: A novel WD-repeat protein, WDR26, inhibits apoptosis of cardiomyocytes induced by oxidative stress. Free Radic Res 46: 777-784, 2012.
91. Blattmann P, Schuberth C, Pepperkok R and Runz H: RNAi-based functional profiling of loci from blood lipid genome-wide association studies identifies genes with cholesterol-regulatory function. PLoS Genet 9: e1003338, 2013.
92. Rothblat GH, De la Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL and Phillips MC: Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 40: 781-796, 1999. (Pubitemid 29220519)
93. Hoekstra M, van Berkel TJ and van Eck M: Scavenger receptor BI: a multi-purpose player in cholesterol and steroid metabolism. World J Gastroenterol 16: 5916-5924, 2010.
94. Maitra U and Li L: Molecular mechanisms responsible for the reduced expression of cholesterol transporters from macrophages by low-dose endotoxin. Arterioscler Thromb Vasc Biol 33: 24-33, 2013.
95. Saddar S, Carriere V, Lee WR, et al: Scavenger receptor class B type I is a plasma membrane cholesterol sensor. Circ Res 112: 140-151, 2013.
96. Crestani M, De Fabiani E, Caruso D, et al: LXR (liver X receptor) and HNF-4 (hepatocyte nuclear factor-4): key regulators in reverse cholesterol transport. Biochem Soc Trans 32: 92-96, 2004. (Pubitemid 38283022)
97. Tu K, Zheng X, Yin G, Zan X, Yao Y and Liu Q: Evaluation of Fbxw7 expression and its correlation with expression of SREBP-1 in a mouse model of NAFLD. Mol Med Rep 6: 525-530, 2012.
98. Kumadaki S, Karasawa T, Matsuzaka T, et al: Inhibition of ubiquitin ligase F-box and WD repeat domain-containing 7alpha (Fbw7alpha) causes hepatosteatosis through Kruppel-like factor 5 (KLF5)/peroxisome proliferator-activated receptor gamma2 (PPARgamma2) pathway but not SREBP-1c protein in mice. J Biol Chem 286: 40835-40846, 2011.
99. Ntambi JM, Miyazaki M and Dobrzyn A: Regulation of stearoyl-CoA desaturase expression. Lipids 39: 1061-1065, 2004. (Pubitemid 40129048)
100. Wang J, Ban MR, Zou GY, et al: Polygenic determinants of severe hypertriglyceridemia. Hum Mol Genet 17: 2894-2899, 2008.
101. Kathiresan S, Melander O, Guiducci C, et al: Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 40: 189-197, 2008. (Pubitemid 351171402)
102. Verma S, Tabb MM and Blumberg B: Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells. BMC Cancer 9: 3, 2009.
103. Pani G, Galeotti T and Chiarugi P: Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 29: 351-378, 2010.
104. Montero J, Morales A, Llacuna L, et al: Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res 68: 5246-5256, 2008.
105. Garcia-Ruiz C, Mari M, Colell A, et al: Mitochondrial cholesterol in health and disease. Histol Histopathol 24: 117-132, 2009.
106. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, et al: Ketones and lactate 'fuel' tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9: 3506-3514, 2010.
107. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, et al: The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 9: 1960-1971, 2010.
108. Behrend L, Henderson G and Zwacka RM: Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 31: 1441-1444, 2003. (Pubitemid 38030996)
109. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Saavedra E and Moreno-Sánchez R: The causes of cancer revisited: 'Mitochondrial malignancy' and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med 31: 145-170, 2010.
110. Sone H, Akanuma H and Fukuda T: Oxygenomics in environmental stress. Redox Rep 15: 98-114, 2010.